Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...

Current and Future Treatments for Alzheimer’s Disease and other Dementias



Sudha Seshadri, M.D.
Founding Director
Glenn Biggs Institute for Alzheimer’s & Neurodegenerative Diseases
The University of Texas Health San Antonio

Learning Objectives
  • Review new insights into the pathophysiology of Alzheimer’s Disease and other dementias
  • Summarize the current guideline recommendations for symptomatic treatment of Alzheimer’s Disease and other dementias
  • Compare the impact of symptomatic versus disease-modifying treatments for dementia
  • Explore novel disease-modifying treatments for Alzheimer’s disease and other dementias

Activity Description

This program consists of 1 video and downloadable resources in PDF format.  To begin, take the ungraded pre-test for the module below.  Review the video and handout(s), then complete the post-test ( > 70% within 5 attempts) and evaluation. CPE credit will automatically upload to CPE Monitor (allow 7 days). 
 

Continuing Education Credit
 
The University of Texas at Austin College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  This online activity is approved for 0.10 CEUs (1.00 contact hour) of continuing education credit. In order to receive 1.00 contact hour of CE credit, the participant must complete the online pre-test (ungraded), watch the included video in its entirety, pass the online post-test ( > 70% within 5 attempts), and complete the online evaluation.  Upon successful completion of the course evaluation, continuing pharmacy education credits will automatically be uploaded to CPE Monitor (allow 7 days). 
Please make sure NABP profile ID and date of birth (month/year) are entered correctly under learner's profile in this system.
 

 

Fee

$5.00

CE Hours

1.00

CE Units

0.100

Activity Type

  • Knowledge

Target Audience(s)

  • Pharmacists

 

 

 

Current and Future Treatments for Alzheimer’s Disease and other Dementias

About the Faculty

Sudha Seshadri, M.D.
Founding Director
Glenn Biggs Institute for Alzheimer’s & Neurodegenerative Diseases
The University of Texas Health San Antonio

Dr. Sudha Seshadri completed her M.B.B.S. from the Christian Medical College, MadrasUniversity, and her M.D. in internal medicine and D.M. in neurology from the All India Institute ofMedical Sciences, New Delhi, India. Additionally, she has completed a residency in neurology at the Boston University School of Medicine and a fellowship in the neurobiology of Aging andAlzheimer Disease at the University of Massachusetts Medical Center. She has previously worked as assistant professor of neurology at the All India Institute of Medical Sciences and professor of neurology and attending neurologist at the Boston University School of Medicine.As founding director of the Glenn Biggs Institute for Alzheimer’s & Neurodegenerative Diseases,Dr. Seshadri will oversee, integrate, and coordinate all activities of the Biggs Institute, which will share the space of UT Health’s Barshop Institute for Longevity and Aging Studies.Dr. Seshadri enjoys a superb reputation in both science and clinical care and is a recognized thought leader in Alzheimer’s disease having recently co-authored position papers disseminated by the National Academy of Sciences on Preventing Cognitive Decline and Dementia: A WayForward, and by the American Heart Association with a paper titled Defining Optimal BrainHealth in Adults. She has lectured extensively, nationally and internationally, on Alzheimer’s disease, dementia and the genetics of stroke and vascular brain injury.She is a senior investigator for the seminal Framingham Heart Study, has had peer reviewed research continuously funded by the National Institutes of Health for 10 years, and currently serves as the principal investigator on eight NIH U01 or R01 grants.

Disclosure:  Sudha Seshadri has no relevant financial relationship(s) with commercial interests or conflicts of interest to disclose.


 

Activity Number

0067-0000-20-111-H04-P

Release Date: Oct 15, 2020
Credit Expiration Date: Oct 15, 2022

CE Hours

1.00